Nge-8 kaSeptemba, ngo-2025, i-InnoCare Pharma ibhengeze ukuba i-HIBRUKA (orelabrutinib) ivunyiwe yi-Health Sciences Authority (HSA) yaseSingapore ukuze inyange izigulane zabantu abadala abane-relapse okanye i-refractory marginal zone lymphoma (R/R MZL).
Okwangoku, kusekho iimvavanyo ezininzi zeklinikhi zobuchwepheshe obutsha bokulwa nomhlaza eTshayina obufuna izigulane. Iingcebiso ngamayeza amatsha kunye nobuchwepheshe, ungaqhagamshelana neSebe leMicimbi yeZibhedlele ze-Oncology zaseBeijing South Region.
Inombolo yefowuni: 4008803716
I-ID ye-WeChat: 17801183037
Email：myimmnet@163.com
I-Marginal zone lymphoma (MZL) yi-B-cell non-Hodgkin's lymphoma (NHL) engasebenziyo echaphazela kakhulu izigulane ezikwiminyaka ephakathi kunye nezikhulileyo. Ukwanda kwe-MZL ngonyaka kuyanda kwihlabathi liphela. Emva konyango lokuqala, izigulane ezine-R/R MZL azinazo iindlela zonyango ezisebenzayo.
Ngo-Epreli 2025, i-orelabrutinib yamkelwe eTshayina kunyango lokuqala lwezigulane ezine-chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL). I-Orelabrutinib ikwavunyiwe kunyango lwezinye iimpawu ezintathu eTshayina, kuquka i-relapse and refractory (R/R) CLL/SLL, r/r mantle cell lymphoma (R/R MCL) kunye ne-r/r marginal zone lymphoma (R/R MZL) yaseTshayina, zonke ezi zigutyungelwe kuLuhlu lwaMayeza eSizwe okubuyiselwa kwemali eTshayina.
Ukusebenza, uKhuseleko, kunye nokuqiqa kwe-Orelabrutinib Plus Obinutuzumab kwi-Systemic Treatment-Naive Marginal Zone Lymphoma: Uphononongo lwe-Prospective Cohort lubonise ukuba kulo lonke uphando kunye nangexesha lonyango lokungeniswa, izinga lokuphendula lilonke (ORR) liyi-100%. Izigulane ezintathu ezinempendulo engaphelelanga (PR) emva konyango lokungeniswa zifumene impendulo epheleleyo (CR) ngexesha lokugcinwa.
Uvavanyo lwe-ADCC lubonise ukuba i-orelabrutinib xa idibene ne-obinutuzumab ibangele impendulo ye-ADCC esebenzayo kakhulu kwimigca yeseli ye-TMD-8 kunye ne-REC-1.
Okwangoku, kusekho iimvavanyo ezininzi zeklinikhi zobuchwepheshe obutsha bokulwa nomhlaza eTshayina obufuna izigulane. Iingcebiso ngamayeza amatsha kunye nobuchwepheshe, ungaqhagamshelana neSebe leMicimbi yeZibhedlele ze-Oncology zaseBeijing South Region.
Inombolo yefowuni: 4008803716
I-ID ye-WeChat: 17801183037
Email：myimmnet@163.com
Ixesha leposi: Sep-09-2025